Beta3 adrenergic agonists
CA 2415331 A1 · Owner: Ruehter, Gerd · Inventors: Sall, Daniel Jon; Remick, David Michael; Siegel, Miles Goodman
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to a .beta.3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and therefore, is useful for , treating Type II diabetes and/or obesity. The compound can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition the compound can , be used to reduced neurogenic inflammation or as an antidepressant agent. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 9, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 9, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 9, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.